CXCL4L1-fibstatin cooperation inhibits tumor angiogenesis, lymphangiogenesis and metastasis

Microvascular Research

Volumn 89, Issue , 2013, Pages 25-33

  Prats, A C ^a   Van den Berghe, L ^b,c   Rayssac, A ^a   Ainaoui, N ^a   Morfoisse, F ^b,c   Pujol, F ^a   Legonidec, S ^a   Bikfalvi, A ^b,d   Prats, H ^b,c   Pyronnet, S ^b,c   Garmy Susini, B ^b,c  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b INSERM   (France)

^c CANCER RESEARCH CENTER OF TOULOUSE   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOSTATIN; FIBSTATIN; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; PLATELET FACTOR 4 VARIANT 1; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNAL RIBOSOME ENTRY SITE; LYMPH NODE; LYMPHANGIOGENESIS; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

ADENO-ASSOCIATED VIRUS;

ANIMALS; CARRIER PROTEINS; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN; DISEASE PROGRESSION; DNA, COMPLEMENTARY; DRUG COMBINATIONS; ENDOSTATINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LAMININ; LYMPHANGIOGENESIS; MEMBRANE PROTEINS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET FACTOR 4; PROTEOGLYCANS; RECOMBINANT PROTEINS;

EID: 84883188532     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2013.05.005     Document Type: Article

References (32)

1. Avraamides C.J., Garmy-Susini B., et al. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 2008, 8(8):604-617.
2. Bossard C., Van Den Berghe L., et al. Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide. Cancer Res. 2004, 64(20):7507-7512.
3. Brideau G., Makinen M.J., et al. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res. 2007, 67(24):11528-11535.
4. Byers L.A., Heymach J.V. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin. Lung Cancer 2007, 8(Suppl. 2):S79-S85.
5. Campochiaro P.A. Gene transfer for neovascular age-related macular degeneration. Hum. Gene Ther. 2011, 22(5):523-529.
6. Campochiaro P.A. Gene transfer for ocular neovascularization and macular edema. Gene Ther. 2012, 19(2):121-126. (Epub 2011 Nov 10) (Feb). 10.1038/gt.2011.164.
7. Cui K., Zhao W., et al. The CXCR4-CXCL12 pathway facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis. J. Surg. Res. 2011, 171(1):143-150.
8. Delluc-Clavieres A., Le Bec C., et al. Efficient gene transfer in skeletal muscle with AAV-derived bicistronic vector using the FGF-1 IRES. Gene Ther. 2008, 15(15):1090-1098.
9. Dubrac A., Quemener C., et al. Functional divergence between 2 chemokines is conferred by single amino acid change. Blood 2010, 116(22):4703-4711.
10. Foy K.C., Liu Z., et al. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J. Biol. Chem. 2011, 286(15):13626-13637.
11. Garmy-Susini B., Makale M., et al. Methods to study lymphatic vessel integrins. Methods Enzymol. 2007, 426:415-438.
12. Garmy-Susini B., Avraamides C.J., et al. Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res. 2010, 70(8):3042-3051.
13. Gordis L., Gold E.B. Epidemiology of pancreatic cancer. World J. Surg. 1984, 8(6):808-821.
14. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2002, 2(10):727-739.
15. Kim K.S., Park Y.S. Antitumor effects of angiostatin K1-3 and endostatin genes coadministered by the hydrodynamics-based transfection method. Oncol. Res. 2005, 15(7-8):343-350.
16. Liu Y., Thor A., et al. Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J. Biol. Chem. 1999, 274(19):13338-13344.
17. Mulder K., Koski S., et al. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget 2010, 1(7):515-529.
18. Mumprecht V., Detmar M. Lymphangiogenesis and cancer metastasis. J. Cell. Mol. Med. 2009, 13(8A):1405-1416.
19. Nagy J.A., Vasile E., et al. VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. Cold Spring Harb. Symp. Quant. Biol. 2002, 67:227-237.
20. Nierodzik M.L., Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006, 10(5):355-362.
21. O'Reilly M.S., Boehm T., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88(2):277-285.
22. Ou J., Li J., et al. Endostatin suppresses colorectal tumor-induced lymphangiogenesis by inhibiting expression of fibronectin extra domain A and integrin alpha9. J. Cell. Biochem. 2011, 112(8):2106-2114.
23. Paez-Ribes M., Allen E., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15(3):220-231.
24. Ponnazhagan S., Mahendra G., et al. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res. 2004, 64(5):1781-1787.
25. Rayssac A., Neveu C., et al. IRES-based vector coexpressing FGF2 and Cyr61 provides synergistic and safe therapeutics of lower limb ischemia. Mol. Ther. 2009, 17(12):2010-2019.
26. Renyi-Vamos F., Tovari J., et al. Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin. Cancer Res. 2005, 11(20):7344-7353.
27. Rupp C.C., Linehan D.C. Extended lymphadenectomy in the surgery of pancreatic adenocarcinoma and its relation to quality improvement issues. J. Surg. Oncol. 2009, 99(4):207-214.
28. Sirven A., Ravet E., et al. Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol. Ther. 2001, 3(4):438-448.
29. Skobe M., Hawighorst T., et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001, 7(2):192-198.
30. Stacker S.A., Caesar C., et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 2001, 7(2):186-191.
31. Struyf S., Burdick M.D., et al. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res. 2007, 67(12):5940-5948.
32. Tammela T., Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010, 140(4):460-476.